Keytruda (pembrolizumab) has been approved for use in combination with chemoradiotherapy (CRT) for patients with high-risk locally advanced cervical cancer; in other words, those with stage III to ...

Medscape Medical News, March 19, 2024 SGO 2024 QOL Not Harmed With Add-On Pembrolizumab in Cervical Cancer Adding pembrolizumab to concurrent chemoradiotherapy does not affect quality of life in ...

Merck (NYSE:MRK) announced Saturday that its ant-PD-1 therapy Keytruda (pembrolizumab) reached the main goal in a Phase 3 ...

For information, the company have announced that the trial for pembrolizumab plus lenvatinib in endometrial cancer did not meet its primary endpoint and therefore they will no longer be pursuing a ...

This study is looking at whether doctors can use a urine test to screen for cancer of the cervix. This trial is looking at pembrolizumab for cervical cancer that has spread into the surrounding tissue ...

DelveInsight’s Advanced Cervical Cancer pipeline report depicts a robust space with 70+ active players working to develop 75+ ...

At the final analysis, the coprimary endpoint of overall survival was not met. Topline data were announced from a phase 3 trial evaluating pembrolizumab (Keytruda ®) plus lenvatinib (Lenvima ...

Medscape Medical News, September 20, 2024 ESMO 2024 Pembrolizumab Plus CCRT Improves Overall Survival Patients with locally advanced cervical cancer were randomized to receive either pembrolizumab ...

This study is looking at whether doctors can use a urine test to screen for cancer of the cervix. This trial is looking at pembrolizumab for cervical cancer that has spread into the surrounding tissue ...